31 results about "Lung injury" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

The invention discloses a construction and evaluation method of an organ chip for evaluating smoke lung injury, which comprises the following steps of: determining the design size and the thickness of the chip, determining to take a corresponding amount of Sylgard 184 base glue according to the design size and the required thickness of the lung organ chip, mixing the base glue and a curing agent according to the weight ratio, and performing extrusion molding to obtain the organ chip for evaluating smoke lung injury. The method comprises the following steps: selecting a PET film with a proper aperture, simulating a gas exchange barrier between pulmonary alveoli and capillaries, cutting according to the size of a cavity constructed by a chip, pretreating the PET film, namely soaking the PET film with absolute ethyl alcohol before use, removing possible impurities and oil stains on the surface of the film, washing with deionized water, and drying to obtain the PET film. The construction method of the smoke lung injury organ chip is simple, stable performance of cells in the chip can be guaranteed in the culture process, and cell culture and gas and nutrient substance exchange simulation are facilitated.

The present disclosure provides a unique solution for assisting in the ventilation of lungs of subject that is performed by artificial mechanical ventilator. The solution of the present invention improves the efficiency of the ventilation effect by applying desired pressure profile on portions of the upper body part of the subject in synchronization with the mechanical ventilator operation, thereby creating a desired pressure profile or gradient in the lungs airways to ensure that air pumped into the lungs by the mechanical ventilator spreads more homogeneously in the lungs than without the intervention of the system of the present invention. The application of pressure is determined after analyzing data from sensors of the system that are placed on a plurality of portions on the upper body part of the subject and data received from the mechanical ventilator. These sensors sense data indicative of the ventilation profile within the lungs, i.e. pressure profile along different portions of the lung. The system provides extra-thoracic pressure on the rib cage according to pre-defined and adaptive algorithms based on the physiological status, the respiratory mechanics, and the inhomogeneous nature of lung injury. By applying pressure to the hyperventilated areas and reducing the transpulmonary pressure gradient, the system prevents hyperinflation trauma to the open areas and atelecto-trauma to the closed areas. The system is synchronized with the mechanical ventilator and adapt to changes in the patient's respiratory mechanics.

The invention provides a manufacturing method of a silica-induced lung injury rat model and application of Erchen decoction. A manufacturing method of a silica-induced lung injury rat model is used for researching medical application and pathological effects of Erchen decoction in treatment of silicosis, traditional Chinese medicines in the Erchen decoction comprise Pinellia ternate, dried orange peel, Poria cocos, honey-fried licorice root, dark plum and ginger, and the manufacturing method is characterized by comprising the following steps: S1, experimental animals and grouping; the invention provides a manufacturing method of a silica-induced lung injury rat model and an application of Erchen soup, and systematically verifies and deepens a microecological mechanism of silicosis on the basis of early discovery; a new accurate diagnosis and treatment target is provided; the modern breakthrough of pharmacological research of traditional Chinese medicines is realized; the dysbacteriosis type silicosis model established by the invention has the advantages of simple and convenient modeling method, good repeatability, clear pathological characteristics and clear key target spots.

The invention discloses an application of a pyroptosis pathway inhibitor in protection of plateau brain impact lung injury, the pyroptosis pathway inhibitor is applied to preparation of a medicine for preventing and / or treating lung injury caused by plateau brain impact injury, the pyroptosis pathway inhibitor acts on a Caspase-1 / GSDMD signal pathway, the inhibitor comprises a Caspase-1 inhibitor, an ASC inhibitor or a GSDMD-D inhibitor, and the inhibitor comprises a Caspase-1 inhibitor, an ASC inhibitor or a GSDMD-D inhibitor. The medicine is used for improving lung function impairment caused by plateau brain impact injury. The lung function indexes comprise at least one of the maximum inspiration flow rate, the maximum expiration flow rate, the respiratory rate and the accumulated volume, and the medicine is used for relieving lung tissue pathological injury caused by the plateau brain impact injury; the pathological injury comprises at least one of pulmonary alveolar wall thickening, inflammatory cell infiltration, pulmonary alveolar cavity internal hemorrhage and pulmonary alveolar rupture and fusion into pulmonary bulla. The invention provides a new target spot and strategy for clinical prevention and treatment of the secondary lung injury of the plateau craniocerebral impact injury.

The invention discloses an application of S100A9 in treatment of lung injury caused by liver ischemia reperfusion. A liver ischemia reperfusion animal model is utilized to find that S100A9 is closely related to lung injury caused by liver ischemia reperfusion. Lung injury caused by liver ischemia reperfusion can be effectively relieved by knocking out the S100A9 gene or inhibiting a downstream signal channel mediated by the S100A9. In addition, it is also found that the S100A9 expression level has very strong correlation with lung injury after liver transplantation by collecting patients clinically subjected to liver transplantation. Research results of the invention show that S100A9 is a diagnosis and treatment marker for lung injury caused by hepatic ischemia reperfusion.

This invention provides a drug related to lung injury and its application, the drug comprising gabapentin and / or pharmaceutically acceptable salts of gabapentin; the drug reduces the levels of MPO and NOX2 in lung tissue; the application is for the preparation of formulations for the prevention or treatment of lung injury using gabapentin and / or pharmaceutically acceptable salts of gabapentin, or for the study of the mechanism of lung injury caused by surgery; the study is related to manufacturing and application in industry; the drug can prevent or treat damage caused by lung interruption and re-inflation during lung surgery, and has good application prospects in industry.

The invention relates to a membrane bionic nanomaterial for treating sepsis lung injury as well as a preparation method and application of the membrane bionic nanomaterial. The preparation method of the membrane bionic nanomaterial for treating the sepsis lung injury comprises the following steps: S1, preparing a targeted peptide DSPE-PEG-Tyr storage solution; s2, preparation of MM-Tyr is carried out; s3, preparing a solution; s4, loading of effective active ingredients; and S5, construction of the membrane bionic nano material Tyr-MM (at) PLGA / G + F. The membrane bionic nanomaterial Tyr-MM-coated PLG / G + F provided by the invention integrates sepsis lung injury treatment and inflammation response functions, can respond to an inflammation signal of a focus part of sepsis lung injury, is delivered to the focus part in a targeted manner, releases two effective active components, exerts synergistic antibacterial, anti-inflammatory and immunomodulatory effects, and has a good application prospect in treatment of sepsis lung injury. The key link of the pathologic process of sepsis is effectively intervened, and the huge potential of preventing and treating sepsis lung injury is shown.

The present invention belongs to the technical field of biomedicine, and specifically relates to the application of 9-hydroxy pentadecanoic acid in the preparation of a drug for preventing and treating lung injury. By establishing a mouse model of radon inhalation-induced lung injury, the present invention found that after exposure to different radon levels, the body weight of the mice decreased, the lung coefficient increased, the tidal volume, minute ventilation volume and maximum inspiratory flow of the lungs decreased, the respiratory function was inhibited, the alveolar cavities of the mice were abnormally dilated, the lung septum was thickened and fractured, accompanied by more fibrin exudation, obvious inflammatory infiltration appeared beside the bronchi, congestion occurred in the small blood vessels, and collagen deposition occurred in the lung tissue, which could lead to the occurrence of pulmonary fibrosis and cause lung injury. By intragastric administration of 9-hydroxy pentadecanoic acid, the above phenomena can be effectively inhibited. Therefore, 9-hydroxy pentadecanoic acid can be used for the prevention and treatment of lung injury, especially for the prevention and treatment of lung injury caused by radon exposure.

A system for classifying smoke inhalation lung injury includes a memory that stores instructions; and a processor that executes the instructions. When executed by the processor, the instructions cause the system to: obtain a set of lung abnormalities for a classification model; apply the classification model to the set of lung abnormalities for generating a risk score for severity of smoke inhalation lung injury; generate, by the classification model, the risk score for severity of smoke inhalation lung injury.

The invention belongs to the technical field of biology, and particularly relates to a micropeptide CIM53 as well as a coding gene and application thereof. The amino acid sequence of the micropeptide CIM53 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the gene for coding the micropeptide CIM53 is as shown in SEQ ID NO. 2. According to the invention, it is found for the first time that cell overexpression of CIM53 can down-regulate various cytokines induced by Poly (I: C), IFN-beta and LPS; the CIM53 remarkably improves the survival rate of C57BL / 6J mice treated by LPS, relieves LPS-induced lung injury of the mice, and plays an important role in preparation of drugs for treating cytokine storm-related diseases; the CIM53 can obviously improve lung injury of mice infected by the H1N1 influenza virus, can obviously improve the survival rate of the mice when being used together with OSV medicines, and has an important effect on preparation of medicines for treating diseases related to virus-induced cytokine storm.

The present invention relates to a medicament for treating lung injury, in particular, the present invention provides the use of a Annexin for the manufacture of a composition or formulation for one or more uses selected from the group consisting of: (i) preventing and / or treating lung injury; (ii) reducing the number of neutrophils.

The invention provides a method for evaluating drug lung injury in vitro through a lung organ model, and relates to the technical field of biological medicine. Comprising the following steps: preparing five different culture mediums, culturing the hESC by using the different culture mediums, inducing the hESC to respectively carry out directional endoderm cell differentiation, anterior intestinal bulb differentiation and lung organ construction, and evaluating the drug lung injury by using a prepared lung organ model. The lung organ model prepared by the invention is similar to the cell composition of the human lung organ, can accurately reflect the toxic effect of the medicine on the lung in the physiological environment in the human body, and can be repeatedly obtained in quantity, so that clinical risks and ethical constraints are avoided; the sensitivity of the lung to different drugs can be reflected through cell DNA injury, and the method is suitable for in-vitro repeatable and high-throughput rapid evaluation of drug lung injury.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The invention discloses a method for evaluating sepsis lung injury by detecting the crosslinking degree of type VI collagen, and relates to the technical field of medical diagnosis and monitoring. The method at least comprises the following steps: S1, firstly, carrying out sample collection and multi-index detection; s2, performing imaging feature extraction, and automatically identifying fine structure changes in the chest CT image by using a deep learning algorithm; and S3, based on the feature extraction in the S2, establishing a corresponding quality control algorithm, a basic damage scoring model, a dynamic progress prediction model and a comprehensive risk assessment model. The accurate, early-stage and dynamic sepsis lung injury assessment method is provided through multi-dimensional biomarker detection, iconography feature extraction and a dynamic algorithm model, the early diagnosis rate of sepsis lung injury can be remarkably improved, the disease progress can be effectively monitored, the treatment effect can be effectively assessed, and the application prospect is wide. The method has remarkable clinical application prospects and economic benefits, and particularly has important value in intensive care and formulation of personalized treatment schemes.

Methods for treating lung injury by administration of an anti-CCL8 antibody are disclosed. Also disclosed are methods for evaluating lung therapies by use of an animal model of the genus Peromyscus.

The invention discloses application of alpha1-acid glycoprotein in preparation of a medicine for treating lung injury caused by acute pancreatitis, and belongs to the technical field of biological medicine. An acute pancreatitis lung injury model is constructed through ORM1 gene knockout mice, the mice are divided into a normal group, a model group and a treatment group for research, target organ pathological injury degree detection, immunohistochemical analysis and serum inflammatory factor expression quantity are performed after injection administration, and the curative effect difference of the gene knockout mice and wild type mice is compared, so that the acute pancreatitis lung injury model is established. And the treatment effect of the alpha1-acid glycoprotein on the acute pancreatitis lung injury is verified. The invention provides a key basis for research, development and preparation of drugs for treating acute pancreatitis lung injury, and has important clinical application value.

The invention belongs to the technical field of biomedicine, and particularly relates to an acute plateau low-pressure low-oxygen lung injury mouse model building method which comprises the following steps: selecting SPF-level male SD (Sprague Dawley) rats for adaptive feeding; performing low-oxygen sensitivity pretreatment on the rats after the adaptive feeding is finished; debugging the closed low-pressure oxygen cabin to an initial standard state, putting the pretreated rat into the closed low-pressure oxygen cabin, and closing the cabin door; performing staged low-pressure and low-oxygen synergistic exposure on the rats in the cabin, and obtaining an acute plateau low-pressure and low-oxygen lung injury rat model after the exposure is finished; according to the method, a staged low-pressure low-oxygen collaborative exposure design of pressure dominated low oxygen and oxygen concentration collaborative low oxygen is adopted, so that the core characteristic that the natural plateau oxygen partial pressure is gradually reduced along with the altitude is completely reproduced; the periodic fluctuation mode of the oxygen concentration cooperation stage further fits the oxygen concentration change of the real plateau environment, and it is ensured that the model can truly reproduce the progressive pathological process from the initial hypoxia stress to the acute inflammation injury.

The invention discloses a radix puerariae tea drink and application thereof in preparation of a medicine for treating lung injury caused by arsenic poisoning, and belongs to the field of biological medicine. The invention provides a kudzuvine root tea drink prepared by soaking kudzuvine root blocks in boiling water, and provides application of the kudzuvine root tea drink in preparation of a medicine for treating arsenic poisoning lung injury. Experimental results show that for sodium arsenite exposed mice, the radix puerariae tea drink provided by the invention can effectively relieve immune microenvironment disorder in lung cells, maintain the oxidation-reduction steady state of lungs and remarkably improve mitochondrial injury and mitochondrial autophagic flow retardation in the lung cells. The radix puerariae tea drink provided by the invention has a remarkable effect of relieving and treating lung injury caused by arsenic poisoning, and the preparation method of the radix puerariae tea drink is simple, and the radix puerariae tea drink is suitable for daily drinking and long-term disease control. The invention provides a new medicine raw material for treating lung injury caused by arsenic poisoning, and has great medical value and wide application prospect.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

[Problem] To provide: a sheet for biological tissue regeneration treatment which regenerates a biological tissue; a sheet for repairing a nerve injury; a sheet for repairing a brain injury; a sheet for repairing a spinal cord injury; a sheet for repairing a lung injury; a sheet for repairing a peritoneal injury; a sheet for repairing a vascular injury; a culture sheet; and a regeneration treatment method. [Solution] This sheet for biological tissue regeneration treatment comprises: a first surface which includes a roughened surface to be phagocytosed by cells of an in-vivo tissue; and a second surface which is disposed on the reverse side from the first surface. The roughened surface contains polytetrafluoroethylene as a main component.

The invention discloses a combined metabolic marker for judging the improvement effect of combination of NMN and glucose on mouse lung tissue injury under low-pressure and low-oxygen conditions as well as a kit and application of the combined metabolic marker. The combined metabolic marker comprises lipid metabolite oxidized fatty acid FA (18: 0; o), an oxidized fatty acid FA (19: 5; o) and an oxidized fatty acid FA (22: 6; the combined metabolic marker can be used for judging the improvement effect of combination of NMN and glucose on mouse lung tissue injury under low-pressure and low-oxygen conditions. By detecting the relative concentration of lipid metabolites in a mouse lung tissue sample intervened by combination of NMN and glucose, calculating a combined marker variable P based on a binary logistic regression equation and a determined intercept point value, the improvement condition of the mouse lung injury caused by combination treatment of NMN and glucose on a low-oxygen mouse is judged, and the improvement condition of the mouse lung injury caused by combination treatment of NMN and glucose is judged. The combined marker composed of the three markers has a good application prospect.

The invention belongs to the technical field of medical biology, provides application of citric acid in preparation of a reagent for improving mouse lung function impairment induced by subchronic contamination B [a] P, and further relates to application of citric acid in preparation of a reagent for antagonizing lung tissue cell ferroptosis induced by subchronic contamination B [a] P so as to improve lung function impairment. A C57BL / 6J mouse is taken as a research object, the relationship between mouse lung tissue cell ferroptosis induced by subchronic contamination B [a] P and lung injury is observed, and the effect of CA antagonism of lung tissue cell ferroptosis in B [a] P induced lung function injury is discussed. The result shows that the subchronic contamination B [a] P can induce mouse lung tissue cell ferroptosis, so that the mouse lung function is damaged. CA can antagonize mouse lung tissue ferroptosis induced by subchronic contamination B [a] P and improve mouse lung function impairment caused by ferroptosis. A certain theoretical research is provided for treatment of sub-chronic contamination B [a] P induced lung function impairment.

The utility model provides a negative pressure thoracic cavity closed drainage device capable of adjusting air pressure. The negative pressure thoracic cavity closed drainage device comprises a drainage bottle, a drainage tube, a negative pressure air tube and an adjusting tube. A first through hole and a second through hole are formed in the top surface of the drainage bottle; one end of the drainage tube is inserted into the inner cavity from the first through hole and extends below the fluid, and the other end is communicated with the thoracic cavity; one end of the negative-pressure air pipe is communicated with the inner cavity through the second through hole, and the other end is connected with a negative-pressure suction mechanism; a third through hole is formed in the top face of the drainage bottle, and the bottom end of the adjusting pipe enters the inner cavity from the third through hole and extends to the position below the fluid. The adjusting tube is additionally arranged on the drainage bottle, and the depth of the adjusting tube under the water surface is adjusted up and down, so that the effect of effectively adjusting the negative pressure in the drainage bottle is achieved, and on the basis of continuously sucking out gas in the thoracic cavity of a patient with poor lung expansion function and large lung crevasse under the negative pressure and increasing the rescue success rate, the negative pressure in the thoracic cavity of the patient is reduced. And lung injury of the patient caused by overlarge negative pressure in the bottle can be avoided.

The invention provides application of Pt and Pd-S in preparation of a medicine for treating lung injury, and belongs to the field of biological pharmacy. The medicine with the treatment effect on the lung injury and the medicine composition of the medicine have the lung tissue targeting function, have the application potential in preparation of the medicine for treating the lung injury and can be used for clinical treatment of the lung injury.

A ventilation device and a ventilation regulation and control method are disclosed. The ventilation device includes a ventilation apparatus, a ventilation pipeline, a sensor assembly which includes a pressure sensor and a flow amount sensor, and a processor. The processor is configured to obtain a monitoring pressure acquired by the pressure sensor and / or the airway flow rate acquired by the flow amount sensor during mechanical ventilation of patient; determine a parameter value of a respiratory drive parameter according to the monitoring pressure and / or the airway flow rate; perform a statistical analysis on the parameter value of the respiratory drive parameter to obtain a first target value; compare the first target value with a preset first range; and adjust and / or prompt to adjust a parameter value of a ventilation support parameter, according to a comparison result, thus reducing lung injury or diaphragm fatigue and achieving a better ventilation effect.

The present application belongs to the technical field of lung injury treatment and relates to the use of soy extract for the prevention or treatment of uranium-induced lung injury. More specifically, this application relates to the use of soy extract for the manufacture of a medicament with one or more of the following uses: a) improvement of pulmonary fibrosis in a uranium-exposed individual; b) increase of uranium excretion capacity in a uranium-exposed individual; and c) prevention or treatment of uranium-induced lung injury. In this application, the protective effect of soy extract (SE) was investigated in a mouse model of uranium-induced lung injury. The results showed that soy extract can improve pulmonary fibrosis in a uranium-exposed individual.Treatment with soy extract (SE) alleviated uranium-induced pulmonary fibrosis, simultaneously reducing the expression of α-SMA, TGF-β1, and Hyp, and improving uranium-induced pathological changes in lung tissue. Compared to the uranium group, the SE+U group showed a significant reduction in lung uranium concentration of 18.8%. Hematoxylin and eosin staining also revealed a significant reduction in the histological infiltration of inflammatory cells. Soy extract thus possesses a certain protective effect against uranium-induced lung damage.

This invention provides a lung-moistening lotion and its application in the preparation of products for preventing lung injury caused by environmental pollutants. The invention uses loquat leaf extract and bamboo culm extract as active ingredients, employing a low-temperature treatment and mild water extraction process, and compounding them in a specific ratio. The synergistic effect of these two ingredients significantly reduces intracellular reactive oxygen species levels, restores antioxidant defense capabilities, inhibits abnormal expression of inflammatory factors, and improves lung function-related indicators. The product of this invention has high safety, is suitable for long-term consumption, and can be used to prepare functional foods, health foods, or respiratory care products. It also shows promising application prospects in the prevention of lung injury related to nanoplastics.